Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway

25 Sept 2004

Abstract excerpt

Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Research Advances
Share to Genetics and Neurodevelopmental Disorders
Share to Neonatal Respiratory Health Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15564131
DOI: 10.1016/j.ymthe.2004.08.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis AirwayPMID 15564131Read ↗

Nucleic Acid Therapies for Cystic FibrosisSemantic proximity Read ↗

Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway EpitheliaSemantic proximity Read ↗

SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia From Donors with Cystic FibrosisSemantic proximity Read ↗

Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.Semantic proximity Read ↗

Oligonucleotide-based therapies for cystic fibrosis.Semantic proximity Read ↗

SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal DegradationSemantic proximity Read ↗

Novel molecular approaches to cystic fibrosis gene therapySemantic proximity Read ↗

Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosisSemantic proximity Read ↗

A systemically delivered AAV-CFTR gene therapy for cystic fibrosisSemantic proximity Read ↗

Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.Semantic proximity Read ↗

Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.Semantic proximity Read ↗

Inhalation of SP-101 Followed by Inhaled Doxorubicin Results in Robust and Durable hCFTRΔR Transgene Expression in the Airways of Wild-Type and Cystic Fibrosis FerretsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.